Introducing the next generation in exosome isolation
Early Access Program
The ExoRelease Kit is coming soon in 2021. However, if you'd like to be the first to level up, and unlock the potential of pure, functional exosomes yourself, we encourage you to apply today to our early access program.
We are selecting a limited number of early customers to work with. You will unlock not only the ability to explore this isolation platform in your own lab, but also get access to early discounted pricing.
If you think you'd be a good candidate reach out and apply today. What are you waiting for?
ExoRelease Exosome Isolation Kit
Are you looking for reduced production cycling time and minimizing operator related errors by increasing automation and control to facilitate continuous processing and improve energy and material use? When holistic analytical approach is supported with state-of-the art data processing we guarantee that quality is built into products by design.
Solutions for Every Lab
Are you looking for a source of pure, subtyped exosomes? Maybe you're tired of complicated, and tedious isolation steps. Get the best results, with pure clean exosomes unlike any other.
Immunomagnetic exosome separation is based on antibodies coupled to magnetic beads. During incubation, the antibody/bead complex binds to exosomes expressing the corresponding epitope on the exosome surface. When the suspension is placed into a magnetic field, magnetically labeled exosomes are retained, while unlabeled exosomes and other EV material can be removed. To recover the exosomes, the sample is removed from the magnetic field and placed into the ExoRelease Tool. From here you can do a final separation of the exosomes from the bead complex.
ExoRelease Beads are provided in a column-free format. Features of this technology and the benefits are explained below.
Next-generation biology and biotechnology demand revolutionary production materials. Our ExoRelease Kit serves as robust enabling tools for the 'active' purification of exosomes from virtually any source.
Exosome Biology and Function
Imagine what you can do with pure, functional exosomes. In a recent study (M. He*, Microfluidic On-demand Engineering of Exosomes towards Cancer Immunotherapy, Lab on a Chip, 2019, 19, 1877 – 1886)
Clara Biotech Exorelease exosomes are superior for therapeutic delivery with ~2x improvement in cell uptake over the "gold standard"
Diagnostics & Biomarkers
For those working with exosome sourced biomarkers for DNA, RNA or proteomic analysis you understand the wealth of information contained within exosomes, but there are also new challenges in getting strong signals. At Clara Biotech, we are passionate about providing the best solutions for exosome analysis.
Simple, Repeatable Workflow with minimal steps
Check out our simple and straightforward workflow with less than 2 hours of hands-on time.
Works with virtually any biofluid source containing exosomes.
For general exosome capture you have the option of our off the shelf PAN Capture Human Reactive (combination of CD9, CD63, and CD81) antibody conjugated beads.
However, if you are looking for something more specific, reach out to us so that we can discuss your specific project requirements. We can work with most commercially available antibodies.
Instructions for Use (not publically available at this time)
Safety Data Sheet (not publically available at this time)
MISEV Standards 2018 - Fully compliant
2021 Preprint - Nano Pom-poms Prepared Highly Specific Extracellular Vesicles Expand the Detectable Cancer Biomarkers (https://doi.org/10.1101/2021.02.21.432188)
2019 - Microfluidic on-demand engineering of exosomes towards cancer immunotherapy
2018 - Microfluidic engineering of exosomes_ editing cellular messages for precision therapeutics
2016 - Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured graphene oxide / polydopamine coating (2016)
2016 - Microfluidic Exosome Analysis Toward Liquid Biopsy for Cancer (2016)
2016 - A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis